AnaptysBio Inc

ANAB remains in an advancing mean-reversion regime flagged by the Bullish Pivot Point, with price supported by converged EMAs and the 50-day SMA near $57. Medium-term bias is bullish, but short-term momentum is neutral amid consolidation, so entries should be deferred. We will stalk for a shallow pullback into the EMA/50-SMA zone or a decisive breakout above recent highs before engaging.

• ↑Robust share momentum reflects growing investor confidence in ANAB.
• ↑Analysts have recently upgraded earnings estimates, indicating rising optimism.
• ↓Negative earnings yield underscores weak return generation.